These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 30810537)

  • 21. Construction and validation of m
    Miao Y; Su B; Tang X; Wang J; Quan W; Chen Y; Mi D
    IET Syst Biol; 2022 Apr; 16(2):59-71. PubMed ID: 35174637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression pattern of m
    He X; Tan L; Ni J; Shen G
    Cancer Gene Ther; 2021 Apr; 28(3-4):188-196. PubMed ID: 32759989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contributions and prognostic values of m
    Liu Y; Guo X; Zhao M; Ao H; Leng X; Liu M; Wu C; Ma J; Zhu J
    J Cell Physiol; 2020 Sep; 235(9):6043-6057. PubMed ID: 32052446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploration of the Role of m
    Wei Q; Yang D; Liu X; Zhao H; Yang Y; Xu J; Liu T; Yi P
    Front Genet; 2021; 12():650554. PubMed ID: 34149801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Risk Signature Consisting of Eight m
    Guan S; He Y; Su Y; Zhou L
    Cell Mol Neurobiol; 2022 Nov; 42(8):2733-2743. PubMed ID: 34432221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomics and Prognosis Analysis of Epithelial-Mesenchymal Transition in Glioma.
    Tao C; Huang K; Shi J; Hu Q; Li K; Zhu X
    Front Oncol; 2020; 10():183. PubMed ID: 32154177
    [No Abstract]   [Full Text] [Related]  

  • 29. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
    Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
    Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Identification of Critical m
    Xu J; Liu Y; Liu J; Xu T; Cheng G; Shou Y; Tong J; Liu L; Zhou L; Xiao W; Xiong Z; Yuan C; Chen Z; Liu D; Yang H; Liang H; Chen K; Zhang X
    Front Genet; 2020; 11():602485. PubMed ID: 33343639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Prognosis, and Immune Phenotype of Glioma.
    Qi Y; Chen D; Lu Q; Yao Y; Ji C
    Dis Markers; 2019; 2019():3917040. PubMed ID: 31885736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
    Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
    J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and Potential Biomarkers of Regulators for M7G RNA Modification in Gliomas.
    Chen Z; Zhang Z; Ding W; Zhang JH; Tan ZL; Mei YR; He W; Wang XJ
    Front Neurol; 2022; 13():886246. PubMed ID: 35614925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic and Multi-Omics Prognostic Analysis of Lysine Acetylation Regulators in Glioma.
    Tu Z; Wu L; Luo H; Li J; Lv S; Ye M; Liu F; Tao C; Zhu X; Huang K
    Front Mol Biosci; 2021; 8():587516. PubMed ID: 33718432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas.
    Guan X; Luo L; Begum G; Kohanbash G; Song Q; Rao A; Amankulor N; Sun B; Sun D; Jia W
    J Exp Clin Cancer Res; 2018 Oct; 37(1):255. PubMed ID: 30333031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
    Zhang C; Li J; Wang H; Song SW
    Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas.
    Qian Z; Li Y; Fan X; Zhang C; Wang Y; Jiang T; Liu X
    J Neurooncol; 2018 Mar; 137(1):127-137. PubMed ID: 29204839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. m6A RNA Methylation Regulators Participate in the Malignant Progression and Have Clinical Prognostic Value in Lung Adenocarcinoma.
    Li F; Wang H; Huang H; Zhang L; Wang D; Wan Y
    Front Genet; 2020; 11():994. PubMed ID: 33193582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
    Patil V; Mahalingam K
    Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.